San Diego, CA, United States of America

Isan Chen

USPTO Granted Patents = 10 

 

 

Average Co-Inventor Count = 1.3

ph-index = 4

Forward Citations = 56(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovator in Cancer Treatment: Isan Chen

Introduction:

Isan Chen, a prolific inventor based in San Diego, CA, has made significant contributions to the field of cancer treatment with an impressive portfolio of 9 patents to his name. His innovative work in developing anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer has garnered attention in the medical community.

Latest Patents:

Isan Chen's latest patents focus on the development of anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer. These patents detail novel methods for effectively treating this challenging form of cancer, showcasing Chen's dedication to finding new solutions for patients in need.

Career Highlights:

Chen has honed his expertise through his work with esteemed companies such as Aragon Pharmaceuticals, Inc. and Genentech, Inc. His tenure at these organizations has provided him with the platform to translate his innovative ideas into tangible solutions that have the potential to impact the lives of many.

Collaborations:

Throughout his career, Isan Chen has collaborated with skilled professionals in the field, including coworkers like Jeffrey H Hager and Edna Chow Maneval. These collaborations have allowed Chen to leverage diverse perspectives and expertise, leading to enhanced innovation and groundbreaking discoveries.

Conclusion:

Isan Chen stands out as a remarkable inventor in the realm of cancer treatment, with his dedicated efforts yielding significant advancements in the field. His focus on developing anti-androgens for non-metastatic castrate-resistant prostate cancer underscores his commitment to pushing the boundaries of medical innovation. As Chen continues to expand his portfolio and collaborate with industry peers, the future holds promising prospects for further breakthroughs in cancer therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…